Log in

NASDAQ:EYPTEyepoint Pharmaceuticals Stock Price, Forecast & News

$0.86
+0.01 (+1.18 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.83
Now: $0.86
$0.88
50-Day Range
$0.80
MA: $0.88
$0.98
52-Week Range
$0.70
Now: $0.86
$2.69
Volume419,692 shs
Average Volume385,047 shs
Market Capitalization$107.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Read More
Eyepoint Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.32 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.36 million
Book Value$0.13 per share

Profitability

Net Income$-56,790,000.00
Net Margins-196.31%

Miscellaneous

Employees55
Market Cap$107.28 million
Next Earnings DateN/A
OptionableOptionable

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

How has Eyepoint Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYPT shares have decreased by 18.1% and is now trading at $0.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyepoint Pharmaceuticals.

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The company earned $7.49 million during the quarter, compared to analyst estimates of $6.95 million. Eyepoint Pharmaceuticals had a negative return on equity of 286.40% and a negative net margin of 196.31%. View Eyepoint Pharmaceuticals' earnings history.

What price target have analysts set for EYPT?

4 analysts have issued 12 month price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $1.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $3.63 in the next twelve months. This suggests a possible upside of 321.5% from the stock's current price. View analysts' price targets for Eyepoint Pharmaceuticals.

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Press coverage about EYPT stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutEyepoint Pharmaceuticals.

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 2,820,000 shares, a decline of 8.4% from the March 31st total of 3,080,000 shares. Based on an average trading volume of 818,100 shares, the days-to-cover ratio is currently 3.4 days. Approximately 3.5% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Who are some of Eyepoint Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL).

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
  • Mr. David J. Price, Chief Financial Officer (Age 56)
  • Mr. Marty Nazzaro, Sr. VP of Operations

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.06%), Franklin Resources Inc. (3.32%), State Street Corp (0.90%), Geode Capital Management LLC (0.72%), Essex Investment Management Co. LLC (0.51%) and Integrated Advisors Network LLC (0.38%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View institutional ownership trends for Eyepoint Pharmaceuticals.

Which major investors are selling Eyepoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Essex Investment Management Co. LLC, and UBS Group AG. View insider buying and selling activity for Eyepoint Pharmaceuticals.

Which major investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Raymond James Financial Services Advisors Inc., Integrated Advisors Network LLC, Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Two Sigma Investments LP, and BlackRock Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis, and Nancy Lurker. View insider buying and selling activity for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $0.86.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $107.28 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is www.eyepointpharma.com.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.